Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Wahed FTSE USA Shariah ETF (HLAL) vs Medpace Holdings Inc (MEDP) Price & Performance

Wahed FTSE USA Shariah ETFTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Wahed FTSE USA Shariah ETF vs Medpace Holdings Inc — how do they compare? Wahed FTSE USA Shariah ETF trades at $72.94, while Medpace Holdings Inc trades at $601 (market cap $16.66B). Which is the better fit depends on your goals.

HLALMEDP
Sector
Sector/ThematicTechnology
52-Week High
$73.60$620.59
52-Week Low
$55.52$393.42
Market Cap
$16.66B
Enterprise Value
$16.28B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Wahed FTSE USA Shariah ETF

HLAL trades at $72.93, showing minimal daily movement with a slight 0.06% decline. Technical indicators present a mixed picture with bullish moving averages but neutral oscillators, while the stock lacks comprehensive fundamental data for traditional valuation metrics. The upcoming dividend of $0.02 per share scheduled for June 2026 provides a modest income component.

The stock's outlook remains uncertain due to limited financial disclosures. Investment opportunity hinges on future earnings visibility and market positioning, while primary risks include information gaps and market volatility. Further fundamental analysis requires updated SEC filings and earnings reports to assess true valuation potential.

Medpace Holdings Inc

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Wahed FTSE USA Shariah ETF

HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.

Read more on HLAL

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP